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Pre-statin trials reported positive effects of omega-3 fatty acids (n-3 PUFA) in 
cardiovascular disease (CVD), whereas recent studies and meta-analyses have not 
reproduced these results. The effect of n-3 PUFA in patients with familial 




We investigated the effect of n-3 PUFA on the early stage of atherosclerosis in FH 
patients by evaluating in vivo (peripheral arterial tonometry (PAT)) and in vitro 
(plasma asymmetric dimethylarginine (ADMA) and E-selectin) endothelial function.  
 
Methods 
This was a double blind, placebo-controlled crossover study with 34 FH patients on 
statin treatment (mean age 46.6 years). In random order, all individuals were treated 
for three months with high dose n-3 PUFA (2g x2) and three months placebo (olive 
oil, 2g x2), separated by a three months washout period. Anthropometric data, blood 
samples and PAT were collected at four time points.  
 
Results 
There were no significant changes in reactive hyperemia index (RHI) measured by 
PAT after n-3 PUFA compared to placebo, median RHI after n-3 PUFA was 1.98 and 
after placebo 1.96, p=0.51. No significant changes were detected in the soluble 
endothelial marker ADMA (in two different assays) when comparing n-3 PUFA and 
placebo (p=0.92 and 0.14, respectively). Finally, the level of E-selectin did not 
change significantly during the trial, p=0.26. 
 
Conclusion 
Addition of n-3 PUFA to standard lipid-lowering treatment in genetically verified FH 
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ASCEND Omega-3 A Study of Cardiovascular Events in Diabetes, Omega-3 
CHD Coronary heart disease 
CVD Cardiovascular disease 
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JELIS Japanese EPA Lipid Intervention Study 
n-3 PUFA Omega-3 polyunsaturated fatty acid 
PAT Peripheral arterial tonometry 
REDUCE-IT Reduction of cardiovascular events with icosapent ethyl-
intervention trial 
































The cardiovascular effect of marine omega-3 fatty acid (n-3 PUFA) supplement is 
debated. Most trials have focused on secondary prevention of cardiovascular disease 
(CVD), hence, the knowledge regarding primary CVD prevention and n-3 PUFA is 
limited.1 Early secondary CVD prevention n-3 PUFA trials showed reduction in CVD 
and sudden cardiac death,2-6 whereas the majority of the later studies have failed to 
confirm these results.7-12 However, the Reduction of cardiovascular events with 
icosapent ethyl-intervention trial (REDUCE-IT) demonstrated a positive effect of 
eicosapentaenoic acid (EPA) in secondary prevention.13 Statin treatment and varied 
dosage of the n-3 PUFA supplement are among the explanations for the disparate 
trial results.14 Thus, the uncertainty regarding n-3 PUFA supplement and CVD is 
reflected in the current international guidelines from American Heart Association and 
European Atherosclerosis Society.1, 15 American Heart Association recommends n-3 
PUFA supplement for patients with coronary heart disease (CHD) and heart failure 
with reduced ejection fraction, while European Atherosclerosis Society awaits further 
evidence on the n-3 PUFA efficacy before justifying its recommendation. A recent 
meta-analysis including the ten largest n-3 PUFA trials did not support supplement of 
n-3 PUFA as secondary CVD prevention.16 This meta-analysis did not include the 
newly published results from the REDUCE-IT trial. 
 
Individuals with familial hypercholesterolemia (FH) have a high risk of early coronary 
heart disease (CHD), premature mortality and increased morbidity compared to the 
general population.17, 18 Low-density lipoprotein cholesterol lowering is crucial for 
patient outcome, and the introduction of statins has markedly improved the prognosis 
for FH patients. Nonetheless, FH individuals have a high residual risk of CHD despite 
moderate to high intensity treatment with statins,19 and finding efficient means to 
reduce this residual risk, might improve patient outcome. The role of n-3 PUFA-
supplements in the FH population is not well established. Among the n-3 PUFA trials 
in FH, lipid changes in response to n-3 PUFA supplement are the ones most 
studied.20-23 Endothelial dysfunction is considered to be one of the primary events in 
the atherosclerotic process.24 This dysfunction can be evaluated both by measuring 
soluble markers in plasma and by investigating in vivo endothelial response when the 
patient is exposed to various challenges. 
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A previous trial has investigated the effect of n-3 PUFA on the arterial elasticity in 20 
FH patients, and demonstrated reduced systolic blood pressure and improved large 
arterial elasticity.25 In order to reveal a potential effect of n-3 PUFA on endothelial 
function in FH patients, we examined the endothelial function both in vivo and in vitro. 
Our primary endpoint, the in vivo endothelial function, was assessed noninvasively 
by peripheral arterial tonometry (PAT), a well-established method.26-30 The soluble 
endothelial markers asymmetric dimethylarginine (ADMA) and E-selectin served as 
indicators of the in vitro endothelial function.  
 





Patients and Methods: 
 
The data that support the findings of this study are available from the corresponding 
author upon request. The individuals in this study were recruited from Nordland 
Hospital’s lipid clinic (Bodø, Norway), the inclusion and exclusion criteria are listed in 
Table 1. Compliance level was set at 50% intake of study medication.  
 
Study design 
The study was a randomized double-blinded crossover trial (Figure 1). At the first 
hospital visit, patients were randomized to either three months treatment with n-3 
PUFA or three months placebo. After treatment and a subsequent washout period of 
at least three months duration, the individuals received alternate medication in the 
second treatment period. In total there were four hospital visits (at inclusion and after 
three, six and nine months). All four hospital visits included measurement of 
anthropometric data, a physical examination, blood samples and evaluation of the in 
vivo endothelial function. The participants were instructed not to take extra trial 
medicine in case of a forgotten dose. A research nurse was in telephonic contact with 
the participants between the hospital visits. The unused medication was handed in at 
hospital visit number two and four. According to the returned medication, the mean 
compliance was 90% (range 68-100%) in both treatment periods (PUFA or placebo). 
All trial patients were above the pre-determined compliance level of 50%. A 
registration of dietary intake of n-3 PUFA was also completed by the participants. 
The participants were instructed to avoid dietary n-3 PUFA supplements for three 
months before inclusion and throughout the trial, but no specific recommendations 
regarding diet were given. The dietary registration form showed a mean intake of 0.8 
servings of fatty fish per week, with standard deviation 0.5. The mean intake of 





Apotekproduksjon A/S (Oslo, Norway) was responsible for labelling the study 
medication and for the randomization. The randomization was blinded to both study 
individuals and project members. Block randomization was used in order to ensure 
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apportionment of the participants starting with n-3 PUFA and placebo. 
Apotekproduksjon A/S kept the randomization code until the last participant had 
completed the study period.  
 
Study Medication: 
BASF (Lysaker, Norway) provided the n-3 PUFA ethyl esters supplement and the 
placebo capsules. The marine n-3 PUFA supplement was a 1000 mg capsule 
consisting of 460 mg of eicosapentaenoic acid (EPA) and 380 mg docosahexanoic 
acid and was administered in a dose of 4000 mg daily (two capsules twice a day). 
The placebo capsules contained olive oil and was administered in the same manner 
as the n-3 PUFA supplement.    
 
Ethics 
The study was approved by the Regional Ethics Committee of Northern Norway, P 
REK 2011/899, and by the Norwegian Medicines Agency. EUDRACTNR 2012-
000505-68. ClinicalTrials.gov NCT01813006. Informed written consent was obtained 
from all individuals in the study.  
 
Blood samples 
Fasting blood samples were collected at each visit. Routine analyzes for the purpose 
of safety were analyzed consecutively, whereas samples for ADMA and E-selectin 
were frozen at -70C and analyzed in batch at the end of the study. Total cholesterol, 
low-density lipoprotein cholesterol and high-density lipoprotein cholesterol were 
analyzed on an ADVIA®1800 system (Siemens Medical Solutions Diagnostics, 
Japan) using reagents from Siemens Healthcare Diagnostics Ltd.  
 
Assessment of in vivo endothelial function: 
The in vivo endothelial function was assessed by PAT (EndoPAT2000 Itamar 
Medical Ltd, Caesarea, Israel). A pneumatic plethysmograph placed on the subject’s 
index finger detects the digital pulse amplitude. During the test, the blood flow in the 
brachial artery is temporarily stopped by a blood pressure cuff. After five minutes 
occlusion of the artery, the blood flow is restored, and the PAT-device measures the 
changes in digital pulse amplitude during reactive hyperemia, as an expression of the 
subject’s vasodilator function. The reactive hyperemia index (RHI) is the post-
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occlusion to pre-occlusion ratio. PAT was measured at all four hospital visits, all tests 
were performed by the same personnel. The study participants were fasting and 
rested in supine position for five minutes before the examination. The test was 
performed according to the specifications of the manufacturer. RHI values are 
skewed data, hence, nonparametric test was applied.   
 
Assessment of in vitro endothelial function: 
ADMA 
ADMA was analyzed in two different assays, ADMA from Cusabio (Houston, TX) and 
ADMA Xpress from Immundiagnostik (Bensheim, Germany). The detection range for 
ADMA was 7.8-500 ng/m and for ADMA Xpress 0-2 mol/L. Both ADMA assays used 
ethylenediaminetetraacetic acid plasma and were enzyme-linked immunosorbent 
assays. The ADMA assay from Immundiagnostik utilizes the competitive enzyme-
linked immunosorbent assay technique, whereas the assay from Cusabio uses the 
sandwich enzyme-linked immunosorbent assay technique.  
 
E-selectin 
E-selectin (CD62) was analyzed as a singleplex from eBioscience (Thermo Fisher 
Scientific, San Diego, CA) using ethylenediaminetetraacetic acid plasma. E-selectin 
level in plasma was analyzed using the microsphere-based human E-selectin.   
 
All analyzes were performed according to instructions provided by the manufacturers. 
 
Statistics: 
The RHI-results, blood samples and anthropometric measurements after the n-3 
PUFA period and the placebo period respectively, were grouped and statistically 
analyzed independently of intervention order. For RHI, ADMA, ADMA Xpress and E-
selectin, values after the n-3 PUFA period and values after the placebo period were 
compared statistically. Anthropometric data, blood pressure, heart rate and lipids 
were analyzed statistically by comparing baseline values and values after n-3 PUFA, 
and baseline values and values after the placebo period, respectively. The crossover 
study design required paired statistical analysis. Shapiro-Wilk normality test was 
applied on the differences between the periods. For normally distributed differences, 
paired t-test was applied, whereas Wilcoxon Matched-Pairs Signed Rank test was 
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used for not normally distributed differences. A two-tailed P level < 0.05 was 
considered statistically significant. Correction for multiple comparisons was not 
performed. A possible carry-over effect was evaluated by a treatment-period 
interaction analysis, calculated by a two-sample t test or a Mann-Whitney test, 
comparing the patient’s average response in the group starting with n-3 PUFA and 
the group starting with placebo. The statistic work and graphs were done with Prism 































Study population and baseline characteristics 
Thirty-eight patients were enrolled in the study. One person left due to abdominal 
adverse effects (reflux, abdominal pain), one person started fertility treatment, and 
one patient chose to leave the study for unknown reason. Additionally, one of the 
individuals became pregnant at the end of the trial period and was excluded. Thus, 
34 patients completed the nine-month follow-up, 17 females and 17 males. The 
baseline characteristics of the study population are listed in Table 2.  
 
Anthropometry, blood pressure, heart rate and lipids: 
The results of the effect of n-3 PUFA compared to placebo on anthropometric data, 
blood pressure, heart rate and lipids are presented in Table 3. The levels of total 
cholesterol, low-density lipoprotein cholesterol and triglycerides (TG) significantly 
changed after n-3 PUFA compared to baseline. Apart from a slight, but statistically 
significant, increase in hip circumference after treatment with placebo there were no 
changes in the remaining parameters.  
 
Peripheral arterial tonometry: 
The median RHI (first quartile, third quartile) after n-3 PUFA was 1.98 (1.58, 2.46) 
and after placebo 1.96 (1.60, 2.52). There was no significant difference in RHI 
between the n-3 PUFA treatment and the placebo period, p=0.51, median of 
differences 0.07. (Figure 2).  
Eight of the 34 individuals in the present study had one or two RHI measurements 
below 1.35. Among these eight, two individuals had established CHD. None of the 
study participants had RHI results below 1.35 at all four hospital visits. According to 
the manufacturer, an RHI level <1.67 indicates endothelial dysfunction. Twenty-two 
of the 34 participants had RHI levels below 1,67 (11 had one measurement <1.67, 
four had two measurements <1.67, four individuals had three RHI measurements 
<1.67 and three persons had all four measurements of RHI <1.67). Three of the 






Three study participants had ADMA-levels below lower limit of detection. In these 
cases, the individual’s value was set at lower limit of detection (7.8 ng/mL) for use in 
the statistics. The differences between the ADMA-results after n-3 PUFA and 
placebo were not normally distributed and non-parametric method was applied. 
Median (first quartile, third quartile) ADMA after n-3 PUFA was 22.5 ng/mL (13 
ng/mL, 49.3 ng/mL), and the median (first quartile, third quartile) ADMA after placebo 
was 25 ng/mL (14 ng/mL, 49 ng/mL). No significant difference between n-3 PUFA 
and placebo was detected, p=0.92, the median of differences was 0.85 (Figure 3). 
 
ADMA Xpress 
The mean (standard deviation) ADMA Xpress after n-3 PUFA was 177.0 ng/mL (36.0 
ng/mL). After placebo mean (standard deviation) ADMA Xpress was 168.5 ng/mL 
(41.0 ng/mL). The differences between the groups were normally distributed and 
there was no significant difference in ADMA Xpress levels after n-3 PUFA compared 
to placebo, p=0.14, mean of differences -8.7 with 95% confidence interval (-20.6;2.9) 
(Figure 4).  
 
E-selectin: 
The mean (standard deviation) E-selectin after n-3 PUFA was 44.6 ng/mL (19 ng/mL) 
and after placebo mean (standard deviation) E-selectin was 42.9 ng/mL (18 ng/mL). 
The differences between the n-3 PUFA and placebo levels of E-selectin were 
normally distributed, and no statistically significant difference between the periods 
was found, p=0.26, mean of differences -1.7 with 95% confidence interval (-4.7;1.3). 
(Figure 5). 
 
No carry-over effects were detected for any of the parameters examined, as judged 










Identification of drugs reducing the development of atherosclerosis in statin treated 
FH patients is important, considering the residual risk of CVD in this patient group.19 
Furthermore, limiting the use of dietary supplements and medication without 
documented effects on the process of atherosclerosis is necessary to avoid 
polypharmacy in the FH population. 
In the present study the in vivo endothelial function (change in RHI) as measured by 
PAT was unaffected by a three month administration of a high dose n-3 PUFA in FH 
patients, consistent with previous n-3 PUFA and PAT studies.26, 29 The lack of 
change in RHI suggests that n-3 PUFA in addition to statins in FH patients does not 
influence the peripheral hyperemic response. The peripheral hyperemic response 
was linked to coronary microvascular endothelial dysfunction by Bonetti et al, and 
they proposed a reference level of RHI <1.35 to recognize individuals with coronary 
endothelial dysfunction.31 FH patients have impaired endothelial function,24 however 
only three study participants had RHI <1,67 at all four hospital visits. This might imply 
that statin treatment has improved the endothelial function in 31 of the study 
participants in line with a previous report,28 but there was no additional effect after 
supplement with n-3 PUFA.  
 
Endothelial function in vitro assessed by the soluble endothelial markers ADMA (in 
two different assays) and E-selectin were not influenced by addition of n-3 PUFA to 
statins in this trial. The lack of change in ADMA levels is consistent with previous 
studies in children with hyperlipidemia (docosahexanoic acid supplement) and in 
patients with myocardial infarction,32, 33 yet knowledge concerning n-3 PUFA and 
ADMA is limited. ADMA is considered to be an indirect way to investigate the 
endothelial function as ADMA is an inhibitor of nitric oxide synthase, and thus 
decreases the level of the potent vasodilator nitric oxide and subsequently impairs 
the endothelial function. Increased levels of ADMA have previously been linked to 
atherosclerosis risk factors such as hypercholesterolemia and hypertriglyceridemia.34, 
35 However, the participants in these studies were not on statin treatment, and a later 




The level of soluble E-selectin (CD62) also remained unchanged during the trial. E-
selectin is a cell adhesion molecule expressed by cytokine-activated endothelial cells 
and is present both as membrane-bound E-selectin and soluble E-selectin. 
Membrane-bound E-selectin binds to ligands on circulating cells, especially 
monocytes, thus playing an important role in recruiting cells to the endothelium in 
inflammatory processes such as atherosclerosis.37 Soluble E-selectin is considered a 
marker for activated endothelium, and the effect of n-3 PUFA on E-selectin has 
previously been studied in several populations. No effect of n-3 PUFA on E-selectin 
levels was found in a meta-analysis by Yang et al.38 Interestingly, one trial showed a 
significant reduction in E-selectin after seven months of n-3 PUFA supplements in a 
population with hypertriglyceridemia.39 Accordingly, the trial period in our study may 
have been too short to demonstrate E-selectin changes. However, atorvastatin 
treatment in patients with hypercholesterolemia has previously demonstrated 
significant reduction in levels of E-selectin,40 thus statin treatment might have 
reduced the E-selectin levels in our study population prior to the n-3 PUFA 
supplement.  
 
Apart from a minor increase in hip circumference after the placebo period, 
anthropometric data such as waist circumference and body mass index, as well as 
blood pressure and heart rate did not change significantly during the present trial 
(table 3). These finding are in line with previous publications, both in prior 
randomized controlled trials26, 41 and a recent Cochrane review including 79 n-3 
PUFA -trials of at least 12 months duration.42 In contrast, multiple physiologic effects 
have been linked to n-3 PUFA, such as blood pressure-lowering and reduction of 
heart rate.43, 44 However, these meta-analyses are partly based on pre-statin trials 
which might explain this inconsistency. A consistent finding in n-3 PUFA trials is a 
reduction in TG,45 and this effect was also present in our study. Although the 
absolute reduction was small, this change in TG was statistically significant (p<0.001) 
and represented a 27% reduction in TG after n-3 PUFA supplementation compared 
to placebo, in line with previous publications.29, 46 Furthermore, the reduction in TG 
levels in the treatment group provides evidence that the participants had a high level 
of compliance. 
The treatment period was 12 weeks both in the n-3 PUFA and the placebo periods, 
because previous studies have shown effect on endothelial function in shorter or 
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equal trial periods.41, 47, 48 In order to minimize the carryover effect, the blood samples 
after intervention and placebo period were separated by at least six months (washout 
three months + three months treatment). A high dosage of n-3 PUFA was chosen in 
this trial, given the known effect on TG and limited results in selected prior studies 
applying low dosage. Our study population consisted of nine individuals with 
established CHD and 25 individuals without known CHD. The number of individuals 
with CHD was too small to do statistical comparisons between the two groups.  
 
Studies on n-3 PUFA and endothelial function report inconsistent results. Possible 
explanations have previously been pointed out, such as the diversity in study design 
and end points, different study populations (e.g. diabetes mellitus type 2, 
hypertriglyceridemia, healthy individuals, children, obese populations, statin-treated 
patients), various dosage of n-3 PUFA and duration of intervention.  
Several modalities to assess endothelial function have been utilized in n-3 PUFA -
trials. Among the noninvasive modalities, estimation of flow-mediated dilation by 
ultrasound is the one most commonly applied.29, 48-50 PAT has the advantage of being 
operator independent and has been used extensively in CVD research, but not so 
much in trials evaluating the effect of n-3 PUFA on endothelial function. Two previous 
trials assessing individuals not treated with statins, found no significant difference in 
RHI after n-3 PUFA measured by PAT,26, 29 whereas flow-mediated dilation-studies 
have shown positive effects on endothelial function after n-3 PUFA administration to 
cigarette smokers and adults with metabolic syndrome not treated with statins.47, 48 In 
contrast, n-3 PUFA supplement had no effect on endothelial function evaluated by 
flow-mediated dilation in statin treated patients with previous myocardial infarction 
and type 2 diabetes.46, 51 
The same inconsistency is reflected in randomized controlled trials investigating n-3 
PUFA and CVD endpoints.2-11 The recently published results from the A Study of 
Cardiovascular Events in Diabetes, Omega-3-trial (ASCEND Omega-3) concluded 
that n-3 PUFA supplements did not reduce the incidence of serious vascular events 
in diabetic patients without CVD.12 On the other hand, the results from the REDUCE-
IT trial demonstrated reduced risk in the primary end point by supplement of a high 
dose of EPA (4 g icosapent ethyl) in statin treated patients with hypertriglyceridemia 
and established CVD or risk factors.13 The Japanese EPA Lipid Intervention study 
also showed an effect of EPA on major coronary events in a study population using 
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statins4. The EPA dose in our trial medication was 1.84 g, comparable with the EPA 
dose in the JELIS-trial. However, our study medication also contained 1.52 g of 
docosahexanoic acid, and we did not find any significant impact on the endothelial 
function in our FH population. Future studies should investigate the effect of high 
dosage of EPA in the FH population. The potential antiatherogenic effects of n-3 
PUFA are not fully elucidated.52 High levels of TG were linked to decreased 
endothelial function in a report by Kajikawa et al,49 nonetheless, the risk reduction of 
CVD in the REDUCE-IT-trial was not associated with normalization of TG level.13  
   
Strengths and Limitations 
This was a single center study with well-characterized participants. A limited number 
of study personnel performed the measurements and examinations of the patients. 
The study length was three months in both the n-3 PUFA -period and the placebo-
period, which is comparable to previous studies.  
Yet, there are several limitations to consider in the present study. First, our trial 
sample was quite small, but the crossover design increased the power. Second, our 
study population was a mix of primary and secondary prevention of CVD. Third, our 
results may not apply to FH patients with a lower habitual dietary intake of marine n-3 
PUFAs. Last, this study did not measure the n-3 PUFA levels in the blood, however 
all the participants were above the level of compliance set at 50% according to the 
unused medication and the level of TG changed significantly after n-3 PUFA period 
compared to baseline levels.  
 
Conclusion 
In the present study we found no effect on in vivo or in vitro endothelial function by 
adding marine n-3 PUFA to statins in a FH population. Our results do not support 
supplementing FH patients with marine n-3 PUFA.  
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Figure 1. Illustration of the crossover trial design.  
1: First hospital evaluation (HE), 2: Second HE, 3: Third HE, 4: Final HE  
 
Figure 2. Reactive hyperemia index (RHI)-values after Omega-3 fatty acid 
supplement versus placebo, no significant difference. SEM – standard error of mean. 
 
Figure 3. Asymmetric dimethylarginine (ADMA) levels after Omega-3 fatty acid 
supplement versus placebo, no significant difference. SEM – standard error of mean. 
 
Figure 4. Asymmetric dimethylarginine Xpress (ADMA Xpress) levels after Omega-3 
fatty acid supplement versus placebo, no significant difference. SEM – standard error 
of mean. 
 
Figure 5. E-selectin levels after Omega-3 fatty acid supplement versus placebo, no 


























Table 1. Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
 
Age 18-75 yrs Non-compliance 
Genetically verified FH Intake of PUFAs (requires three months 
washout period before enrollment) 
Clinically stable, with and without CVD Pregnancy or planned pregnancy / fertility 
treatment 
Statin treatment >12 months Breastfeeding 
 Cancer and/or severe illness 
 Blood samples at inclusion outside ref. 
range* 









Age (range) 46.6 (18-71) 
Current smoker (%) 5 (15) 
Established coronary disease 
(%) 
9 (27) 
Statin treatment*  
Atorvastatin (%) 22 (65) 
Rosuvastatin (%) 8 (24) 
Simvastatin (%) 4 (12) 










Del Exon 2-3 1 
R395W 1 
T705I 1 
All mutations are low density lipoprotein receptor mutations, except R3500Q which is a mutation of the 
apolipoprotein B gene. A recent Norwegian study reported that 97% of familial hypercholesterolemia was due to 
mutations in the low density lipoprotein receptor LDL receptor,53 and the Gujerat mutation has previously been 






Table 3. Effect of Omega-3 fatty acids versus placebo on anthropometric 
characteristics, blood pressure, heart rate and lipids 
 Baseline After Omega-3 
fatty acids 
After placebo 
BMI (kg/m2) 27.6  5.0 27.6  5.2 27.8  5.2 
Waist (cm) 90  14 91  14 91  15 
Hip (cm) 102  9 103  9 104  10* 
sBP (mmHg) 133  20 131  16 134  21 
dBP (mmHg) 76.6  10 76  10 76  12 
HR (bpm) 68  12 66  8 67  10 




5.0  1.1 
193.4  42.5 
 
4.6  0.8* 
177.9  30.9* 
 
5.0  1.1 





3.2  1.0 
123.7  38.7 
 
2.8  0.9** 
108.3  34.8** 
 
3.2  0.9 





1.4  0.5 
54.1  19.3 
 
1.4  0.4 
54.1  15.5 
 
1.4  0.4 






1.09  0.59 
96.5  52.3 
 
0.84  0.39*** 
74.4  34.5*** 
 
1.15  0.86 
101.9  76.2 
Data are presented as mean SD.  
BMI – body mass index, Waist – waist circumference, Hip – Hip circumference, sBP – systolic blood 
pressure, dBP – diastolic blood pressure, HR – heart rate, LDL-C – low-density lipoprotein 
cholesterol, HDL-C – high density lipoprotein cholesterol, TG – triglycerides. 
The p-value was calculated as the difference between baseline values and after Omega-3 fatty 
acids period or the difference between baseline values and after placebo period using paired t-test 
(normally distributed difference) or Wilcoxon Matched Pairs Signed Rank test (not normally 
distributed difference).  
*       p  0.05 
     p  0.01 
   p  0.0001 
 
 
 
 
 
 
